RxSight sees FY24 revenue $139M-$140M, consensus $139.64M

Gross margin in the range of 70% to 71%, up from previous guidance range of 68% to 70%; and Operating expenses at the low end of its previously provided guidance range of $135.0 to $136.0 million, including non-cash stock-based compensation expense, now also expected at the lower end of the previous guidance range of $29.0 to $30.0 million.